55,916 Shares in Nabriva Therapeutics PLC – (NASDAQ:NBRV) Bought by Creative Planning

Creative Planning bought a new position in shares of Nabriva Therapeutics PLC – (NASDAQ:NBRV) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 55,916 shares of the biotechnology company’s stock, valued at approximately $112,000.

A number of other hedge funds also recently made changes to their positions in NBRV. FMR LLC increased its position in Nabriva Therapeutics by 77.0% during the first quarter. FMR LLC now owns 3,261,500 shares of the biotechnology company’s stock worth $7,958,000 after acquiring an additional 1,418,800 shares during the period. Commonwealth Equity Services LLC increased its position in Nabriva Therapeutics by 30.0% during the second quarter. Commonwealth Equity Services LLC now owns 65,010 shares of the biotechnology company’s stock worth $157,000 after acquiring an additional 15,000 shares during the period. Wells Fargo & Company MN bought a new position in Nabriva Therapeutics during the second quarter worth $169,000. JPMorgan Chase & Co. increased its position in Nabriva Therapeutics by 92.7% during the second quarter. JPMorgan Chase & Co. now owns 323,857 shares of the biotechnology company’s stock worth $719,000 after acquiring an additional 155,815 shares during the period. Finally, Renaissance Technologies LLC increased its position in Nabriva Therapeutics by 51.8% during the second quarter. Renaissance Technologies LLC now owns 1,299,365 shares of the biotechnology company’s stock worth $3,157,000 after acquiring an additional 443,600 shares during the period. 3.82% of the stock is currently owned by institutional investors and hedge funds.

In other Nabriva Therapeutics news, CEO Theodore R. Schroeder purchased 50,000 shares of the firm’s stock in a transaction on Tuesday, August 27th. The shares were purchased at an average price of $1.79 per share, for a total transaction of $89,500.00. Following the completion of the purchase, the chief executive officer now directly owns 5,786 shares of the company’s stock, valued at $10,356.94. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last quarter, insiders have acquired 64,977 shares of company stock worth $119,951 and have sold 21,773 shares worth $45,186. 3.32% of the stock is owned by insiders.

NBRV opened at $1.84 on Tuesday. Nabriva Therapeutics PLC – has a fifty-two week low of $1.12 and a fifty-two week high of $3.27. The company has a debt-to-equity ratio of 0.87, a current ratio of 5.81 and a quick ratio of 5.67. The firm’s fifty day moving average price is $1.92 and its two-hundred day moving average price is $2.19. The company has a market capitalization of $1.46 billion, a P/E ratio of -1.13 and a beta of 2.42.

Nabriva Therapeutics (NASDAQ:NBRV) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.04. Nabriva Therapeutics had a negative net margin of 910.45% and a negative return on equity of 171.36%. The firm had revenue of $6.92 million for the quarter, compared to the consensus estimate of $1.23 million. On average, equities research analysts expect that Nabriva Therapeutics PLC – will post -1.12 EPS for the current fiscal year.

NBRV has been the topic of a number of recent research reports. Northland Securities set a $13.00 price target on shares of Nabriva Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 16th. Needham & Company LLC reiterated a “buy” rating on shares of Nabriva Therapeutics in a research note on Wednesday, November 13th. BidaskClub downgraded shares of Nabriva Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. Zacks Investment Research downgraded shares of Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 23rd. Finally, Wedbush reiterated an “outperform” rating and set a $7.00 price target on shares of Nabriva Therapeutics in a research note on Friday. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. Nabriva Therapeutics currently has an average rating of “Hold” and a consensus price target of $6.79.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Featured Article: Understanding the two types of arbitrage

Want to see what other hedge funds are holding NBRV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nabriva Therapeutics PLC – (NASDAQ:NBRV).

Institutional Ownership by Quarter for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.